"GeneCentric...today announced the launch of its EXpressCTcm (Expression Signatures Through Circulating Tumor Signals) liquid biopsy platform that allows the value of tissue RNA expression and epigenomics to be realized in liquid biopsy. EXpressCT expands the application of the company’s pipeline of RNA-based gene expression signatures and diagnostic tests to cell-free DNA (cfDNA) liquid biopsy samples, including blood and urine."